Xilio Therapeutics, Inc.

NasdaqGS XLO

Xilio Therapeutics, Inc. Price to Book Ratio (P/B) on January 14, 2025

Xilio Therapeutics, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Xilio Therapeutics, Inc. 52-week high Price to Book Ratio (P/B) is 1.34 on April 01, 2024, which is NA below the current Price to Book Ratio (P/B).
Xilio Therapeutics, Inc. 52-week low Price to Book Ratio (P/B) is 0.79 on June 25, 2024, which is NA below the current Price to Book Ratio (P/B).
Xilio Therapeutics, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.01.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: XLO

Xilio Therapeutics, Inc.

CEO	Dr. Rene Russo BCPS, Pharm.D.
IPO Date	Oct. 22, 2021
Location	United States
Headquarters	828 Winter Street
Employees	73
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years